Meta-analysis · people

PT-141: side-effect dropouts far higher than placebo in re-analysis

Checked against the paper Meta-analysisPublished by PepVault

The takeaway

This re-analysis of the main PT-141 trials in women with low sexual desire found modest benefits and much higher odds of quitting due to side effects than on placebo, and it concludes the drug is generally not useful.

Kind
Meta-analysis
Studied in
People
Published
2021
Journal
J Sex Res

What they tested

This re-analysis asked whether the published results of two Phase III bremelanotide trials for hypoactive sexual desire disorder (HSDD, persistently low sexual desire) in women gave a complete picture of benefit and harm.

How the study was done

A single-author meta-analysis that pooled data from two 24-week Phase III trials, drawn from the FDA New Drug Application. It also compared the original published report against the trials' protocols.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking PT-141? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Benefits were similar to the original report's, but the author judged them modest and measured on post hoc outcomes of questionable validity. Women on bremelanotide had much higher odds of leaving the trial because of side effects (odds ratio 11.98, 95% CI 3.74-38.37, number needed to harm 6). They were also less likely to both finish the trial and choose to join the open-label follow-up study (odds ratio 0.30, number needed to harm 4), which the author read as a preference for placebo. The original paper left out 72.72% of the outcomes listed in the protocols and presented 15 secondary measures the protocols never listed.

What it doesn’t show

This is one author's re-analysis of two existing trials, not a new trial. Treating trial completion plus joining the follow-up study as a preference for placebo is an indirect measure.

The paper

Spielmans Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women. J Sex Res. 2021.

The compound

More studies on PT-141

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking PT-141? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo